Carregant...
NIMG-72. CEREBRAL BLOW FLOW AND SUV TRENDS IN PET/MRI FOLLOWING BEVACIZUMAB ADMINISTRATION IN GLIOBLASTOMA
BACKGROUND: Bevacizumab (BEV) is an antibody directed at vascular endothelial growth factor (VEGF) and holds FDA approval in recurrent glioblastoma (GBM). Pseudoprogression with necrosis is a common clinical concern in GBM, and BEV is useful in treating both tumor and necrosis. Though conventionally...
Guardat en:
| Publicat a: | Neuro Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693070/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.644 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|